The statements below are Rochon Genova’s account of this case. They reflect allegations or the firm’s position and have not been determined by a court unless a settlement or judgment is noted.
Latest update
On August 23, 2025 , the parties reached a settlement agreement.
Source: Rochon Genova
About This Case
Rexulti is the trademark for the drug, brexpiprazole. Rexulti was approved as treatment for schizophrenia in Canada in February 2017, and as treatment for depression in February 2019.
This national class action, filed in the Quebec Superior Court of Justice, alleges that Otsuka and Lundbeck – the pharmaceutical companies responsible for developing and marketing Rexulti – failed to provide Canadian uses with adequate and timely warnings about the increased risk of impulse control disorders and compulsive behaviours, such as compulsive gambling, compulsive shopping/spending, hypersexuality and binge-eating.
Rexulti is a partial dopamine agonist that is alleged to be substantially similar to the antipsychotic drug aripiprazole (marketed under the trade names Abilify and Abilify Maintena).
Abilify and Abilify Maintena were approved in Canada in 2009 and 2014, and have also been associated with impulse control disorders and compulsive behaviours.
Otsuka developed Abilify and Abilify Maintena and has been commercializing and marketing them in Canada along with Bristol-Myers Squibb Canada Co. and Lundbeck Canada Inc., respectively. The claim alleges that the Otsuka and Lundbeck companies intentionally developed Rexulti to be substantially similar to Abilify, because Abilify was losing patent protection. The similarity in the chemical structures of Rexulti and Abilify/Abilify Maintena was noted in the Health Canada Summary Basis of Decision for Rexulti.
Source: Rochon Genova
Who May Be Eligible
All persons in Canada who were prescribed and used the prescription antipsychotic drug REXULTI during the Class Period starting from February 16, 2017 and who developed one or more of the following Compulsive Behaviours and Impulse Control Disorders: Compulsive Gambling, Hypersexuality, Binge eating, and Compulsive shopping and/or spending.
Source: Rochon Genova
Disclaimer: This information is sourced from Rochon Genova. It is provided for general information only and does not constitute legal advice. Always verify details with the original source before taking any action.
Legal disclaimer: Information on this page is general in nature and does not constitute legal advice. ClaimBar tracks class action settlements and provides updates. Always seek professional legal advice for your specific circumstances.
Did this page answer your question?